Two-dose of Moderna vaccine 93% effective against COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
Two-dose of Moderna vaccine 93% effective against COVID-19. The candidate booster shot can produce a “strong” immune response to the variant
Two-dose of Moderna vaccine 93% effective against COVID-19. Moderna released the financial report on August 5 that the effectiveness of the second dose of the COVID-19 vaccine it developed and produced was still 93% effective six months after the injection. The company also emphasized that in the second phase of human trials, its three candidate enhancements can produce “robust” antibody responses against mutant strains such as Delta variant.
The financial report wrote that the final analysis results of the later study showed that the vaccine protection ability reached 93% after 6 months after the vaccinators completed the standard two-dose vaccination and remained stable for a long time. In contrast, the vaccine protection of Pfizer (45.06, -0.13, -0.29%) and BioNTech dropped to about 84% 6 months after the second injection.
The delta variant has spread in many countries including the United States. The Centers for Disease Control and Prevention (CDC) has emphasized that the variant is extremely contagious and may threaten the elderly who have completed the standard two-dose vaccination. They are getting worse. Moderna also pointed out that this variant may lead to an increase in breakthrough infections.
Moderna said in the financial report that the company is also exploring the possibility of a booster vaccine. The statement said, “In the second phase of human trials, the three candidate boosters can produce a’strong’ antibody response against mutant strains such as Delta variant.” The company said that the test dose of the booster was 50 micrograms, which is the current Half the dose. The data has been submitted to the journal for publication.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on Thursday that federal health officials are “as soon as possible” authorizing a third dose of the COVID-19 vaccine for Americans with weakened immune systems. Germany and France also announced this week that they will provide booster needles starting in September, even if WHO calls on countries to temporarily postpone booster needles.
According to Moderna’s financial report, the company’s COVID-19 vaccine generated sales of US$4.2 billion in the second quarter of this year, higher than the estimated US$4.09 billion. The company said its goal is to produce 800 million to 1 billion doses of the COVID-19 vaccine this year. The company has signed a vaccine contract worth 20 billion U.S. dollars this year, and the value of the 2022 agreement signed by it will also reach 12 billion U.S. dollars.
Moderna’s revenue in the second quarter was 4.35 billion U.S. dollars, higher than the expected 4.2 billion U.S. dollars, and only 67 million U.S. dollars in the same period last year. The company’s net income in the second quarter reached US$2.78 billion, and a loss of US$117 million in the same period last year, equivalent to earnings per share of US$6.46, higher than the expected US$5.96, and a loss of US$0.31 in the same period last year.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
